[{"id":"0eff7476-586f-4316-8e90-c13e90b35147","acronym":"","url":"https://clinicaltrials.gov/study/NCT06046495","created_at":"2023-09-21T15:11:06.648Z","updated_at":"2024-07-02T16:35:07.026Z","phase":"Phase 1","brief_title":"A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06046495","lead_sponsor":"Avistone Biotechnology Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e andamertinib (PLB1004)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 11/29/2023","start_date":" 11/29/2023","primary_txt":" Primary completion: 02/09/2028","primary_completion_date":" 02/09/2028","study_txt":" Completion: 02/09/2028","study_completion_date":" 02/09/2028","last_update_posted":"2024-04-30"},{"id":"9021b348-c6c2-4853-ae85-62dda6a19e1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06281964","created_at":"2024-02-28T18:32:18.616Z","updated_at":"2024-07-02T16:35:17.531Z","phase":"Phase 3","brief_title":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","source_id_and_acronym":"NCT06281964","lead_sponsor":"Avistone Biotechnology Co., Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tyvyt (sintilimab) • pemetrexed • andamertinib (PLB1004)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 327","initiation":"Initiation: 03/30/2024","start_date":" 03/30/2024","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-02-28"},{"id":"fbc3fbe2-d96e-42d5-88ef-58e6d514350a","acronym":"Kannon","url":"https://clinicaltrials.gov/study/NCT06015503","created_at":"2023-08-29T16:10:09.631Z","updated_at":"2024-07-02T16:35:38.737Z","phase":"Phase 2","brief_title":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","source_id_and_acronym":"NCT06015503 - Kannon","lead_sponsor":"Avistone Biotechnology Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e andamertinib (PLB1004)"],"overall_status":"Recruiting","enrollment":" Enrollment 157","initiation":"Initiation: 07/21/2023","start_date":" 07/21/2023","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 09/09/2026","study_completion_date":" 09/09/2026","last_update_posted":"2023-08-29"},{"id":"05ec08fe-22d8-4169-857b-2628b4be1f92","acronym":"","url":"https://clinicaltrials.gov/study/NCT05347628","created_at":"2022-04-26T13:53:59.111Z","updated_at":"2024-07-02T16:35:39.480Z","phase":"Phase 1","brief_title":"Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05347628","lead_sponsor":"Avistone Biotechnology Co., Ltd.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e andamertinib (PLB1004)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 08/25/2020","start_date":" 08/25/2020","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2023-08-21"}]